Progress and prospect of nanotechnology for cardiac fibrosis treatment
Abstract Cardiac fibrosis is the excessive accumulation of extracellular matrix components in the heart, leading to reduced cardiac functionality and heart failure. This review provides an overview of the therapeutic applications of nanotechnology for the treatment of cardiac fibrosis. We first delv...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2023-10-01
|
| Series: | Interdisciplinary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/INMD.20230018 |
| _version_ | 1827778303760531456 |
|---|---|
| author | Samantha L. Gaytan Elfa Beaven Shrikanth S. Gadad Md Nurunnabi |
| author_facet | Samantha L. Gaytan Elfa Beaven Shrikanth S. Gadad Md Nurunnabi |
| author_sort | Samantha L. Gaytan |
| collection | DOAJ |
| description | Abstract Cardiac fibrosis is the excessive accumulation of extracellular matrix components in the heart, leading to reduced cardiac functionality and heart failure. This review provides an overview of the therapeutic applications of nanotechnology for the treatment of cardiac fibrosis. We first delve into the fundamental pathophysiology of cardiac fibrosis, highlighting the key molecular players, including Matrix Metalloproteinases, Transforming Growth Factor‐beta, and several growth factors, cytokines, and signaling molecules. Each target presents a unique opportunity to develop targeted nano‐therapies. We then focus on recent advancements in nanotechnology and how nanoparticles can be engineered to deliver drugs or therapeutic genes. These advanced delivery approaches have shown significant potential to inhibit fibrosis‐promoting factors, thereby mitigating the fibrotic response and potentially reversing disease progression. In addition, we discuss the challenges associated with developing and translating nanotechnology‐based drug delivery systems, including ensuring biocompatibility, safety, and regulatory compliance. This review highlights how nanotechnology can bridge the gap between lab research and clinical practice for treating cardiac fibrosis. |
| first_indexed | 2024-03-11T14:31:08Z |
| format | Article |
| id | doaj.art-626b6b2d4ab545598499ce28d4228698 |
| institution | Directory Open Access Journal |
| issn | 2832-6245 |
| language | English |
| last_indexed | 2024-03-11T14:31:08Z |
| publishDate | 2023-10-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | Interdisciplinary Medicine |
| spelling | doaj.art-626b6b2d4ab545598499ce28d42286982023-10-31T08:13:22ZengWiley-VCHInterdisciplinary Medicine2832-62452023-10-0114n/an/a10.1002/INMD.20230018Progress and prospect of nanotechnology for cardiac fibrosis treatmentSamantha L. Gaytan0Elfa Beaven1Shrikanth S. Gadad2Md Nurunnabi3Department of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USADepartment of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USACenter of Emphasis in Cancer Department of Molecular and Translational Medicine Paul L. Foster School of Medicine Texas Tech University Health Sciences Center El Paso El Paso Texas USADepartment of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USAAbstract Cardiac fibrosis is the excessive accumulation of extracellular matrix components in the heart, leading to reduced cardiac functionality and heart failure. This review provides an overview of the therapeutic applications of nanotechnology for the treatment of cardiac fibrosis. We first delve into the fundamental pathophysiology of cardiac fibrosis, highlighting the key molecular players, including Matrix Metalloproteinases, Transforming Growth Factor‐beta, and several growth factors, cytokines, and signaling molecules. Each target presents a unique opportunity to develop targeted nano‐therapies. We then focus on recent advancements in nanotechnology and how nanoparticles can be engineered to deliver drugs or therapeutic genes. These advanced delivery approaches have shown significant potential to inhibit fibrosis‐promoting factors, thereby mitigating the fibrotic response and potentially reversing disease progression. In addition, we discuss the challenges associated with developing and translating nanotechnology‐based drug delivery systems, including ensuring biocompatibility, safety, and regulatory compliance. This review highlights how nanotechnology can bridge the gap between lab research and clinical practice for treating cardiac fibrosis.https://doi.org/10.1002/INMD.20230018cardiac fibrosisdrug delivery systemsnanomedicinenanotechnologypharmacological interventions |
| spellingShingle | Samantha L. Gaytan Elfa Beaven Shrikanth S. Gadad Md Nurunnabi Progress and prospect of nanotechnology for cardiac fibrosis treatment Interdisciplinary Medicine cardiac fibrosis drug delivery systems nanomedicine nanotechnology pharmacological interventions |
| title | Progress and prospect of nanotechnology for cardiac fibrosis treatment |
| title_full | Progress and prospect of nanotechnology for cardiac fibrosis treatment |
| title_fullStr | Progress and prospect of nanotechnology for cardiac fibrosis treatment |
| title_full_unstemmed | Progress and prospect of nanotechnology for cardiac fibrosis treatment |
| title_short | Progress and prospect of nanotechnology for cardiac fibrosis treatment |
| title_sort | progress and prospect of nanotechnology for cardiac fibrosis treatment |
| topic | cardiac fibrosis drug delivery systems nanomedicine nanotechnology pharmacological interventions |
| url | https://doi.org/10.1002/INMD.20230018 |
| work_keys_str_mv | AT samanthalgaytan progressandprospectofnanotechnologyforcardiacfibrosistreatment AT elfabeaven progressandprospectofnanotechnologyforcardiacfibrosistreatment AT shrikanthsgadad progressandprospectofnanotechnologyforcardiacfibrosistreatment AT mdnurunnabi progressandprospectofnanotechnologyforcardiacfibrosistreatment |